How to cash out in Silicon Valley — without setting off alarms

In the competitive landscape of Silicon Valley, early investors and founders are increasingly exploring the secondary market as a means to liquidate their holdings without attracting negative attention. While the desire to cash out can often be perceived as a betrayal, it has become a necessary maneuver for many as traditional exit opportunities through mergers and acquisitions or IPOs remain scarce. Itamar Novick, founder of Recursive Ventures, emphasizes the importance of secondaries for seed funds, stating, "Whoever's not doing it is not keeping up to speed on the market." Novick, who invested in Deel in 2019, has strategically sold portions of his stake to both existing and new investors, capitalizing on the demand for shares in the now $12 billion HR startup, prior to Deel's legal disputes. However, the secondary market is fraught with challenges. Investors and founders must carefully consider the timing, pricing, and perception of any secondary transactions. A poorly executed sale can send alarming signals to the market about a company’s future, as highlighted by Deedy Das of Menlo Ventures. He notes that a Series A lead selling shares at a $5 billion valuation could raise doubts among later-stage investors about the company's growth prospects. As the market for venture capital secondary investments has surged to approximately $60 billion, the dynamics of these transactions have become increasingly complex. PitchBook reports a significant increase in secondary sales, with demand heavily concentrated among a select few high-performing startups, including OpenAI and SpaceX. Founders often prioritize their companies' growth narratives over the liquidity needs of existing shareholders. This tension is palpable, especially when investors seek to sell stakes in startups with moderate growth rates. Hinge Health co-founder Daniel Perez shares that even minor liquidity requests can stir emotions, as founders view their startups as personal achievements. Dave McClure, of Practical Venture Capital, points out the mismatch between the expectations of early investors and the realities of extended private company lifespans. He notes that many investors are now facing financial pressures that compel them to seek returns sooner than anticipated, particularly as they navigate personal obligations. To address these challenges, Hinge Health facilitated a tender offer in 2022, allowing early investors to realize some returns. Nevertheless, the company faced difficulties in executing subsequent secondary sales due to discrepancies in price expectations. As the secondary market continues to evolve, it is crucial for investors to communicate transparently with founders about their intentions. Establishing a rapport can mitigate potential backlash and facilitate smoother transactions. Moreover, it is common for founders to be granted permission for small liquidity events, particularly when they are discreet and aligned with company goals. Ultimately, while the secondary market is becoming an essential tool for navigating the venture capital landscape, it requires a delicate balance to avoid disrupting the fragile relationships between investors and founders.